Loading...
Linezolid: a promising agent for the treatment of multiple and extensively drug-resistant tuberculosis
Abstract
Tuberculosis is a severe, infectious disease caused by Mycobacterium tuberculosis. The aim of this review was to present the efficacy of linezolid as an agent against multidrug and extensively drug-resistant tuberculosis as gathered from many recent research studies. Linezolid seems to have strongly the potential of being used as an anti-tuberculosis agent because it blocks bacterial ribosomal protein synthesis. Nevertheless caution is required because of the adverse effects it causes, especially when the linezolid daily dosage exceeds 600 mg. The most severe adverse effects include anemia, peripheral neuropathy, optic neuropathy and thrombocytopenia. Still, more trials and research need to be done in order to gather more information and value the cost-benefit dosage of the treatment.
Citations
Altmetric:
Date
2020-09-30
Type
Article
Subject
Respiratory medicine, Communicable diseases, Microbiology. Immunology, Pharmacology
Collections
Citation
Fermeli DD, Marantos TD, Liarakos AD, Panayiotakopoulos GD, Dedes VK, Panoutsopoulos GI. Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis. Folia Med (Plovdiv). 2020 Sep 30;62(3):444-452. doi: 10.3897/folmed.62.e48742.
Journal / Source Title
Folia Medica
DOI
10.3897/folmed.62.e48742.
PMID
33009738
Publisher
Pensoft Publishers
Publisher’s URL
Publisher’s statement
Files
Loading...
Main article
Adobe PDF, 381.51 KB